|Geron Announces Conference Call to Discuss Fourth Quarter and Annual 2011 Financial Results|
Menlo Park, Calif., February 28, 2012 - Geron Corporation (Nasdaq: GERN) will announce its financial results for the fourth quarter and year ended December 31, 2011 on Wednesday, March 7, 2012, after the close of market. Geron's management will host a conference call for analysts and investors on Wednesday, March 7, 2012 at 4:30 p.m. Eastern Time.
Participants can access the conference call live via telephone by dialing 866-383-8119 (U.S.); 617-597-5344 (international). The passcode is 55208232. If accessing the conference call by telephone, please dial in at least 10 minutes early to minimize any delay in joining the call. A live audio-only webcast is also available at
Geron is a biopharmaceutical company developing first-in-class therapies for cancer. The company has two lead product candidates in clinical development, imetelstat and GRN1005. Imetelstat is a telomerase inhibitor that is being evaluated in four Phase 2 clinical trials: metastatic breast cancer, advanced non-small cell lung cancer, essential thrombocythemia and multiple myeloma. GRN1005 is a peptide-drug conjugate that is designed to transport a proven anti-cancer drug, paclitaxel, across the blood brain barrier by targeting the low-density lipoprotein receptor-related proteins (LRPs), specifically LRP1. GRN1005 is being evaluated in two Phase 2 clinical trials: brain metastases arising from breast cancer and brain metastases arising from non-small cell lung cancer. For more information about Geron, visit www.geron.com.